Urology Medical News about standard PSADT

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Does early prostate-specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database Group
BJU International, 06/25/09

Teeter AE et al. – Although early PSA doubling time (ePSADT) and PSADT were significantly related, the overall correlation was poor. However, a long ePSADT correlated well with a long PSADT and is thus useful in identifying men at low risk for prostate cancer-specific mortality very early in their biochemical recurrence (BCR).

Methods

Aim was to determine if ePSADT correlated with 'standard' PSADT following BCR
Spearman's correlation was used to determine the correlation between ePSADT and PSADT among 157 men
These men underwent RP between 1988 and 2005 and had a calculable ePSADT and PSADT
ePSADT threshold was examined and their positive and negative predictive values (PPV and NPV, respectively), to predict aggressive recurrences (PSADT of <9 mo)

Results

ePSADT was significantly, though poorly, correlated with PSADT
ePSADT more accurately predicted PSADT among men with a long ePSADT
Of men with an ePSADT of ≥20 or ≥15 mo, the NPV for an aggressive recurrence was 98% and 93%, respectively
However, among men with an ePSADT of <3 mo, the PPV for aggressive recurrence was only 39%

<< Previous
National prevalence of urogenital pain and prostatitis-like...

Next >>
Informed Consent in High-Risk Renal Transplant Recipients

New Standards Reduce Heparin Potency
JAMA, 11/12/09 Relevance Score: 45%

EHR Firms: Go With Existing Standards
HealthDataManagement, 11/06/09 Relevance Score: 45%

Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma
New England Journal of Medicine, 10/22/09 Relevance Score: 45%

Risperidone dose for schizophrenia
Cochrane Reviews, 10/22/09 Relevance Score: 44%

Is coronary computed tomographic angiography the "gold standard" for coronary artery disease
Journal of Cardiovascular Computed Tomography, 10/16/09 Relevance Score: 44%